Athira Pharma ATHA

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-2.57%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Athira Pharma (ATHA)
    Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

    Key Insights

    Critical company metrics and information
    • Latest Closing Price

      $0.3415
    • Market Cap

      $13.33 Million
    • Price-Earnings Ratio

      -0.12
    • Total Outstanding Shares

      39.04 Million Shares
    • Total Employees

      26
    • Dividend

      No dividend
    • IPO Date

      September 18, 2020
    • SIC Description

      Biological Products, (no Disgnostic Substances)
    • Primary Exchange

      NASDAQ
    • Type

      Common Stock
    • Headquarters

      18706 north creek parkway, suite 104, Bothell, WA, 98011
    • Homepage

      https://www.athira.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$312,000
    Net Cash Flow From Investing Activities, Continuing$64.03 Million
    Net Cash Flow$-90.95 Million
    Net Cash Flow From Investing Activities$64.03 Million
    Net Cash Flow From Operating Activities, Continuing$-97.45 Million
    Net Cash Flow From Operating Activities$-97.45 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Income/Loss From Continuing Operations Before Tax$-110.10 Million
    Basic Earnings Per Share$-2.84
    Costs And Expenses$114.35 Million
    Preferred Stock Dividends And Other Adjustments$0
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$-28.37 Million
    Comprehensive Income/Loss Attributable To Parent$-108.54 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-108.85 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Assets$86.25 Million
    Equity$57.58 Million
    Fixed Assets$2.69 Million
    Other Non-current Assets$1.56 Million
    Accounts Payable$388,000
    Current Liabilities$27.75 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATHA from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.